ImetelChat

NEWS FOR GERON Strong Growth and Strategic Financial Management Bolster Buy Rating for Geron’s Promising Rytelo Drug Jan. 15, 2025, 01:11 AM Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on GERN stock, giving a Buy rating on January 13. Faisal Khurshid has given his B...

NEWS FOR GERON Geron’s Promising Market Growth: Strong Sales Performance and Optimistic Financial Guidance Jan. 13, 2025, 07:09 PM Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on GERN stock, giving a Buy rating yesterday. Stephen Willey has given his Buy rating due to ...

World # 3 is on fire --- (An enlightened investment community that understands the value and potential of Rytelo and future iterations). There is much panic in the investment community involving the world we live in. The world of small biotech companies, in general, and Rytelo's documented successe...

The "Good Vibes" are real and documented , but, at this moment in time, seem to be present primarily on this board only. Most of the investment world does not get their information from this board, where most of the information is honestly posted. Even so, many investment houses realize Rytelo's po...

2025 is a make it or break it year for Rytelo and Geron. The 4 worlds of Geron and Rytelo need to come into play for the stock price to reflex that Rytelo is a "miracle blood cancer medicine" (my comment -- others may disagree). The investment community, which ultimately sets the value (PPS) of Ger...

bp --- I defer to your judgement. I think we all agree that, "The world needs Rytelo. Hopefully, it will live up to its full potential." As far as I can tell, Rytelo is doing very well medically and scientifically. As far as Geron's PPS, that apparently is being controlled by several market forces t...

In these very difficult times, with the world infected with anti-vaxers, climate-change deniers, anti-science types, and with democracy on the cutting board worldwide, Rytelo is a ray of hope.

The world needs Rytelo. Hopefully, it will live up to its full potential.

Some background material on ferroptosis Imetelstat is an acute inducer of lipophagy, promoting the formation of PUFA-containing phospholipids, causing excessive levels of lipid peroxidation and oxidative stress resulting in ferroptosis in AML ============ Ferroptosis, a new form of cell death, and ...

2025 --- The Value of Geron's PPS (in 4 worlds) -- To Be Determined 1/ Rytelo as a needed, demanded, successful blood cancer medicine (MDS, MF, AML and beyond) with clinical combinations and synergies in coming trials (miracle status?) 2/ Geron as a well-managed company with approvals from the FDA ...

Tax loss season generally extents to the first two weeks of January as some decide to take their losses early in the year. Geron, so far, is having a good day which bodes well for the rest of the year, I believe. The market value (as compared to the medical value) will be established as demand for R...

Happy 2025 everyone 2024 turned out to be a very good year for Rytelo from a medical progress standpoint, first with FDA approvals, and now with European follow ups. Even though everything medically with Rytelo seems to go at Tortise speed, it always managed to cross the finish line successfully. W...

A Boost for Blood Health, Geron's RYTELO Gets a Green Light in Europe PUBLISHED / MODIFIED DEC 13 , 2024 CSIMARKET TEAM / CSIMARKET.COM In a significant boost for both Geron Corporation and patients suffering from lower-risk myelodysplastic syndromes (MDS), the Committee for Medicinal Products for ...

Some 2025 thoughts: With Rytelo we are dealing with a fundamental question, that is what something is worth now and what is its potential worth sometime in the future. Investing is always about the future. Some assets increase in value while others decrease in value. The comparison between Rytelo (...

Happy 2025 to all long Geron investors Most of the people on this board believe in Rytelo as a breakthrough blood cancer medicine and are here now primary as investors. As a small biotech company Geron has been fair-game for all sorts of market games. Long-term investors have been on a PPS rollerco...

The investment world, in general, does not understand or believe Rytelo's successes and promise in several blood cancers (MDS, MF, AML & others) with synergies likely in clinical combinations (as indicated by preclinical data). Geron's PPS will improve significantly in Q1 of 2025 as all of the "movi...

Comparing Rytelo's value to bitcoins value: As far as I can tell, Rytelo has met all of the medical and scientific requirements for various blood cancers, with more to come (especially combinations). In the case of bitcoins the value has soared; in Rytelo the value is depressed. As we all know, val...

Rytelo's roots are strong as the flowers are beginning to blossom in MDS, MF and AML. However, the Federal Reserve has just warned us about a market drought (pullback) based upon the next administration's policies (tariffs, tax cuts for the wealthy, fiscal negligence). As good as Rytelo is, Geron's ...

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis December 10, 2024 Business Wire In the dose escalation Part 1 of the study, no dose-lim...

January 2025 -- Medically and scientifically Rytelo has proven to be an important blood cancer medicine (FDA approved, European recommendations in place). No one, at this point in time, knows how good, especially in ongoing combination trials of various sorts. The investment community (long-term, s...

"Good Vibes" from CHMP & EMA for Rytelo. ============ Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS December 13, 2024 FOSTER CITY, Calif.--(BUSINESS WIRE) -- Geron Corporation (Nasdaq: GERN), a comm...